logo mainlogo darklogo main
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
logo main logo darklogo light
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
decresed-nitric-oxide
October 3, 2022

Endothelial dysfunction due to decreased nitric oxide bioavailability in dysglycaemic subjects and first-degree relatives of type 2 diabetic patients

We aimed to investigate oxidative stress and nitrites/nitrates concentrations at baseline and during postprandial hyperglycaemia in 40 first-degree relatives (FDR) of type 2 diabet

Read More
glucagon-peptide
April 24, 2020

Effects of Glucagon Like Peptide 1 Receptor Agonists, Sodium Glucose Cotransporter 2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12 Month Treatment

We investigated the effects of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their combination

Read More
antiduabetic-medications
July 5, 2019

Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow-Up Study

Poor glycaemic control affects myocardial function. We investigated changes in endothelial function and left ventricular (LV) myocardial deformation in poorly controlled type 2 dia

Read More
arterial-stiffness
December 1, 2016

Improvement of arterial stiffness and myocardial deformation in patients with poorly controlled diabetes mellitus type 2 after optimization of antidiabetic medication

Arterial stiffness is associated with increased risk for cardiovascular disease. The purpose of this study is to investigate the arterial stiffness and myocardial deformation in pa

Read More
Type 2 Diabetes Studies
September 25, 2010

Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus

Endothelial glycocalyx perturbation contributes to increased vascular permeability. In the present study we set out to evaluate whether: (1) glycocalyx is perturbed in individuals

Read More
BioRegenx
About BioRegenx
  • Profile
  • People
  • Portfolio
  • Press
  • Contact Us
Get in touch

PO Box 21210
Chattanooga TN, 37424

(800) 398 - 9842

support@bioregenx.com

Headquarters in Chattanooga, TN
Additional Offices in Alpine, UT

Copyright © 2023 BioRegenx, Inc. All rights reserved

7407 Ziegler Rd Chattanooga, TN 37421

(800) 398 - 9842

support@bioregenx.com